4,5α-epoxy-6-methoxy-17-methyl-morphina-6,8(14)-dien-3-ol | 467-04-9

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: 4,5α-epoxy-6-methoxy-17-methyl-morphina-6,8(14)-dien-3-ol
• 英文别名: Gripavin；Oripavin；oripavine；Morphinan-3-ol, 6,7,8,14-tetradehydro-4,5-epoxy-6-methoxy-17-methyl-, (5alpha)-；7-methoxy-3-methyl-2,4,7a,13-tetrahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-9-ol
• CAS: 467-04-9
• 化学式: C₁₈H₁₉NO₃
• 分子量: 297.354
• InChiKey: ZKLXUUYLEHCAMF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  41.9
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Methods for Producing Hydrocodone, Hydromorphone or a Derivative Thereof
  申请人：Orr Brian

  公开号：US20110071297A1

  公开（公告）日：2011-03-24

  The present disclosure generally relates to methods for producing opioid derivatives. More particularly, the present disclosure relates to the preparation of hydromorphone, hydrocodone, or a derivative thereof, by means of a non-catalytic hydrogenation reaction of thebaine, oripavine or a derivative thereof, respectively, using a hydrazide reagent, followed by hydrolysis of the hydrogenated intermediate at a low temperature and for a short period of time. Additionally, the present disclosure relates to a composition comprising the desired hydromorphone, hydrocodone, or a derivative thereof, in combination with a 6-beta compound that is structurally related thereto.

  本公开涉及一般用于生产阿片类衍生物的方法。更具体地，本公开涉及通过非催化氢化反应分别使用肼酰肼试剂对吗啡碱、奥利帕碱或其衍生物进行制备羟吗啡、羟考酮或其衍生物，随后在低温下和短时间内对氢化中间体进行水解。此外，本公开还涉及一种包含所需的羟吗啡、羟考酮或其衍生物与结构相关的6-β化合物的组合物。
• Novel Therapeutic Compounds
  申请人：SESHA Ramesh

  公开号：US20120046272A1

  公开（公告）日：2012-02-23

  The present invention describes a series of therapeutically active compounds of formula I, X—Y—Z  (I) that are useful for treating a disorder in a mammal. In the formula I, X and Z, which may be same or different, are independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic group or substituted or unsubstituted heterocyclylalkyl; and Y is a linker selected from —O—, —S—, —NH—, —(CH 2 ) n —, —CO—, —CONR a —, —NR a CO—, —NR a COO—, —COO—, —CONR a CO—, —CONR a COO— and —COOCOO—. The compounds are useful to treat neurodegenerative disorders, depression, Alzheimer's disease, cognitive disorders, motor disorders, Parkinson's disease, drug addiction, behavioral disorders, inflammatory disorders, stomach disorders, cancers, acute pain, chronic pain and recurrent pain.

  本发明描述了一系列具有治疗活性的化合物，其化学式为I，X—Y—Z  (I)，适用于治疗哺乳动物中的某种疾病。在化学式I中，X和Z，可以相同也可以不同，独立地选择自取代或未取代的烷基、取代或未取代的烯基、取代或未取代的环烷基、取代或未取代的环烷基烷基、取代或未取代的芳基、取代或未取代的芳基烷基、取代或未取代的杂芳基、取代或未取代的杂芳基烷基、取代或未取代的杂环基团或取代或未取代的杂环烷基；Y是从—O—、—S—、—NH—、—(CH2)n—、—CO—、—CONRa—、—NRaCO—、—NRaCOO—、—COO—、—CONRaCO—、—CONRaCOO—和—COOCOO—中选择的连接基团。这些化合物适用于治疗神经退行性疾病、抑郁症、阿尔茨海默病、认知障碍、运动障碍、帕金森病、药物成瘾、行为障碍、炎症性疾病、胃病、癌症、急性疼痛、慢性疼痛和复发性疼痛。
• Use of Oripavine as a Starting Material For Buprenorphine
  申请人：Mannino Anthony

  公开号：US20080312441A1

  公开（公告）日：2008-12-18

  There is provided a method for the synthesis of norbuprenorphine, and ultimately buprenorphine, utilizing oripavine as the starting material. Conventional methods of producing buprenorphine utilize thebaine as the starting material, requiring an O-demethylation step, typically a low to moderate yield transformation. The present use of oripavine as a starting material does not require an O-demethylation step, since the oripavine molecule lacks an O-3 methyl group.

  提供了一种合成诺布派诺啡和最终布洛芬的方法，利用奥利啡作为起始物质。常规合成布洛芬的方法使用吗啡为起始物质，需要进行O-去甲基化步骤，通常产率较低。利用奥利啡作为起始物质不需要进行O-去甲基化步骤，因为奥利啡分子缺少O-3甲基基团。
• Preparation of Oxymorphone from Oripavine
  申请人：Wang Peter X.

  公开号：US20100113787A1

  公开（公告）日：2010-05-06

  An improved method for the preparation of oxymorphone from oripavine is provided. Oripavine is oxidized to form 14-hydroxymorphinone after which the oxidation reaction is quenched to prevent the formation of 1-1′-dimer side products. The 14-hydroxymorphinone is then reduced, typically by catalytic hydrogenation to form oxymorphone. The inventive method disclosed is further applicable to the production of morphinan derivatives.

  提供了一种改进的方法，用于从欧洲罂粟中制备氧吗啡。将欧洲罂粟氧化成14-羟基吗啡酮，然后停止氧化反应以防止1-1'-二聚体副产物的形成。然后将14-羟基吗啡酮还原，通常通过催化氢化反应形成氧吗啡。所披露的创新方法还适用于吗啡类衍生物的生产。
• Processes for the Preparation of Morphinane and Morphinone Compounds
  申请人：Hudlicky Tomas

  公开号：US20120046465A1

  公开（公告）日：2012-02-23

  The present application describes processes for the synthesis of morphinane and morphinone compounds, useful as pharmaceutical agents. Also included are novel intermediates useful in the preparation of these compounds. The process comprises quaternization of oripavine to provide a mixture of the R- and S-isomeric (at the nitrogen) quaternary salts. The R-isomer is readily isolated and converted to various N-(R)-morphinane and N-(S)-morphinone compounds. The R-isomer, S-isomer or a mixture of R- and S-isomers may be demethylated and converted to various morphinane and morphinone compounds.

  本申请描述了合成吗啡烷和吗啡酮化合物的过程，这些化合物可用作药物。还包括在制备这些化合物中有用的新型中间体。该过程包括对烟阔叶芥子碱进行季铵化，以提供R-和S-异构体（在氮上）季铵盐的混合物。R-异构体易于分离并转化为各种N-（R）-吗啡烷和N-（S）-吗啡酮化合物。R-异构体、S-异构体或R-和S-异构体的混合物可以去甲基化并转化为各种吗啡烷和吗啡酮化合物。